Clinical trial · Interventional
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Chinese Patients With Selected Advanced or Metastatic Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor determined the data was no longer needed.
Summary
Brief summary (as posted)
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors in Chinese participants
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BGB-B167 | Drug | — | UNRESOLVED |
| Tislelizumab | Drug | Tislelizumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Phase 1a: Dose Escalation
- description
- Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
- interventionNames
- Drug: BGB-B167
- Drug: Tislelizumab
- type
- EXPERIMENTAL
- label
- Phase 1b: Dose Expansion
- description
- BGB-B167 alone or in combination with tislelizumab (BGB-A317)
- interventionNames
- Drug: BGB-B167
- Drug: Tislelizumab
Primary outcomes (5)
- measure
- Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors previously treated with standard systemic therapy or for whom treatment is not available, not tolerated, or refused, or not expected to provide significant clinical benefit or be tolerated in the medical judgement of the investigator * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 * Adequate organ function as indicated by laboratory values during screening or ≤ 7 days before the first dose of study drug(s) * Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study * Nonsterile men must be willing to use highly effective method of birth control for the duration of the study Exclusion Criteria: * Active leptomeningeal disease or uncontrolled, untreated brain metastasis * Active autoimmune diseases or history of autoimmune diseases that may relapse * Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent * History of severe hypersensitivity reactions to other monoclonal antibody products or their excipients * Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers * Known history of HIV infection.
References
Publications (0)
Data not yet available